Honeywell Solstice® Air
(HFO-1234ze(E) cGMP) to be used in next-generation
respiratory inhalers from AstraZeneca
MORRIS
PLAINS, N.J., Oct. 6, 2022
/PRNewswire/ -- Honeywell (Nasdaq: HON) today announced the
opening of a plant in Baton Rouge,
La., that is the company's first large-scale manufacturing
site for Solstice® Air (HFO-1234ze(E) cGMP), a
near-zero global-warming-potential (GWP) medical propellant for use
in respiratory inhalers.
![(PRNewsfoto/Honeywell) (PRNewsfoto/Honeywell)](https://mma.prnewswire.com/media/1420781/Honeywell_Logo.jpg)
Solstice Air is a non-flammable, near-zero GWP,
non-ozone-depleting, volatile organic compound (VOC)-exempt (per
U.S. EPA and CARB) propellant in clinical development today
for pressurized metered-dose inhalers (pMDIs). AstraZeneca (LON:
AZN), a global leader in the treatment of respiratory diseases such
as asthma and chronic obstructive pulmonary disease (COPD), is
working to incorporate Honeywell's Solstice Air technology, which
is being evaluated for use as a medical propellant and has up to
99.9% less GWP than propellants currently used in inhaled
respiratory medicines. AstraZeneca expects
their triple-combination therapy Breztri Aerosphere
(budesonide/ glycopyrronium/ formoterol fumarate) to be the first
medicine to transition to the next-generation propellant, subject
to regulatory approval, followed by the rest of their pMDI
portfolio.
"AstraZeneca's commercial partnership with Honeywell is an
excellent example of a true commitment to advancing healthcare
innovation to improve outcomes both for patients and the planet,"
said Pablo Panella, senior vice
president, Global Respiratory & Immunology, AstraZeneca.
"Through close collaboration and extensive knowledge sharing
between our two companies, we are committed to bringing the next
generation of inhaled medicines with near-zero GWP propellant to
patients. Honeywell's ability to escalate the production of
Solstice Air at their new manufacturing site will help enable us to
move quickly on this ambition once regulatory approval is
achieved."
"Honeywell is dedicated to supporting our customers'
environmental transformations with ready-now solutions," said
Ken West, president of Honeywell
Advanced Materials. "The opening of this plant in Baton Rouge is Honeywell's first site to
produce medical grade propellant and our continued work with
AstraZeneca offers a critical moment to highlight how Honeywell's
Solstice technology plays an important role in helping the
pharmaceutical industry meet its sustainability goals while
supporting essential care for respiratory patients worldwide."
Honeywell has invested more than one
billion dollars in research, development and new
capacity for its Solstice technology, having anticipated the need
for lower-GWP solutions to combat climate change more than a decade
ago. The Solstice product line, which helps customers lower
their greenhouse gas emissions and improve energy efficiency
without sacrificing end-product performance, includes refrigerants
for supermarkets, air conditioning for cars and trucks, blowing
agents for insulation, propellants for personal and household care
and solvents for cleaning solutions.
Using Honeywell Solstice technology has helped avoid the
potential release of the equivalent of more than 295 million metric
tons of carbon dioxide into the atmosphere so far, equal to the
carbon emissions from nearly 688 million barrels of oil.
Honeywell is committed to achieving carbon
neutrality in its operations and facilities by 2035 and
recently announced a new set of commitments that further
advance its sustainability goals, including committing to set a
science-based target with the Science Based Targets initiative
(SBTi) that will include scope 3 emissions and participation in the
U.S. Department of Energy's Better Climate Challenge. The company
also supports the Paris Climate Agreement. These efforts build on
the company's track record of sharply reducing the greenhouse gas
intensity of its operations and facilities as well as its
decades-long history of innovation to help its customers meet their
environmental and social goals. In 2021, approximately 60% of
Honeywell's new product introduction research and development
investment was directed toward products that improve
environmental and social outcomes for customers.
For more information on Solstice Air (HFO-1234ze(E) cGMP), its
applications, and impact, visit:
https://sustainability.honeywell.com/us/en
For more information about sustainability at AstraZeneca, visit:
https://www.astrazeneca.com/Sustainability.html
Honeywell (www.honeywell.com) delivers industry-specific
solutions that include aerospace products and services; control
technologies for buildings and industry; and performance materials
globally. Our technologies help aircraft, buildings, manufacturing
plants, supply chains, and workers become more connected to make
our world smarter, safer, and more sustainable. For more news and
information on Honeywell, please visit
www.honeywell.com/newsroom.
Media Contact:
Stephanie
Agresti
stephanie.agresti@honeywell.com
973-289-0377
View original content to download
multimedia:https://www.prnewswire.com/news-releases/honeywell-begins-production-of-near-zero-global-warming-potential-medical-propellant-301642799.html
SOURCE Honeywell